These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.
These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.
Society of Hematologic Oncology (SOHO) 14th Annual Meeting
Results 7
Poster Presentation | Sep 9, 2026
AML-1177: Revumenib as Maintenance for AML Following Allogeneic Stem Cell Transplantation
View MaterialPoster Presentation | Sep 9, 2026
AML-703: Real-World Experience With Revumenib: A Single-Center Analysis of Efficacy and Tolerability
View MaterialPoster Presentation | Sep 9, 2026
AML-712: Revumenib + Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Harboring Genetic Alterations in KMT2A, NPM1, or NUP98: Updated Phase 1 Results From SNDX-5613-0708
View MaterialPoster Presentation | Sep 9, 2026
AML-623: Long-Term Follow-Up of Pediatric/Young Adult Patients With Relapsed/Refractory KMT2Ar Acute Leukemia Treated With Revumenib in AUGMENT-101
View MaterialPoster Presentation | Sep 9, 2026
AML-632: Revumenib Therapy Post Hematopoietic Stem Cell Transplant for Patients With Relapsed/Refractory KMT2Ar, NPM1m, and NUP98r Acute Myeloid Leukemia: Post Hoc Analysis of Outcomes From AUGMENT-101
View MaterialPoster Presentation | Sep 9, 2026
AML-773: Efficacy of Revumenib in Acute Myeloid Leukemia Harboring NPM1-Mutated Co-Mutations: Post Hoc Analysis of AUGMENT-101
View MaterialPoster Presentation